ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

PURPLE BIOTECH LTD. Logo
Develops first-in-class therapies targeting tumor immune evasion and drug resistance in cancer.
United States of America
PPBT
Pyxis Oncology, Inc. Logo
Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.
United States of America
PYXS
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland
CRM
Q32 Bio Inc. Logo
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America
QTTB
Quantum Biopharma Ltd. Logo
Develops therapies for brain disorders and a functional beverage for post-alcohol wellness.
United States of America
QNTM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France
ALQGC
QuidelOrtho Corp Logo
Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.
United States of America
QDEL
Quince Therapeutics, Inc. Logo
Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.
United States of America
QNCX
Quoin Pharmaceuticals, Ltd. Logo
Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.
United States of America
QNRX
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea
348080

Talk to a Data Expert

Have a question? We'll get back to you promptly.